| CAS NO: | 401600-86-0 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 401600-86-0 |
| Canonical SMILES | COC1=C(OS(N)(=O)=O)C=C(CC[C@]2([H])[C@]3([H])CC[C@@]4(C)[C@@]2([H])CC[C@@H]4OS(N)(=O)=O)C3=C1 |
| 分子式 | C19H28N2O7S2 |
| 分子量 | 460.6 |
| 溶解度 | DMF: 30 mg/ml,DMF:PBS (pH 7.2) (1:7): 0.1 mg/ml,DMSO: 25 mg/ml,Ethanol: 14 mg/ml |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | STX140 is an estrogen sulfamate with anticancer activities.1 It inhibits steroid sulfatase with IC50 values of 39 and 0.5 nM in placental microsomes and MCF-7 cancer cells, respectively. STX140 also binds to carbonic anhydrase IX and II (Kis = 70 and 270 nM, respectively).2 It inhibits bovine brain tubulin assembly in a cell-free assay (IC50 = 2.2 μM) and tubule formation in human umbilical vein epithelial cells (HUVECs) when used at concentrations of 50 and 100 nM.3,4 STX140 inhibits proliferation of LNCaP, PC3, and MDA-MB-231 cancer cells, as well as wild-type A2780 cancer cells and adriamycin- and cisplatin-resistant A2780 cancer cells (IC50s = 530, 400, 618, 330, 870, and 380 nM, respectively).5,6 It reduces angiogenesis in a Matrigel• plug assay in mice and tumor growth in MCF-7 and MDA-MB-231 mouse xenograft models when used at a dose of 20 mg/kg.7,6 |1. Raobaikady, B., Purohit, A., Chander, S.K., et al. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-methoxyoestradiol-bis-sulphamate. J. Steroid Biochem. Mol. Biol. 84(2-3), 351-358 (2003).|2. Andring, J.T., Dohle, W., Tu, C., et al. 3,17β-Bis-sulfamoyloxy-2-methoxyestra-1,3,5(10)-triene and nonsteroidal sulfamate derivatives inhibit carbonic anhydrase IX: Structure-activity optimization for isoform selectivity. J. Med. Chem. 62(4), 2202-2212 (2019).|3. Jourdan, F., Leese, M.P., Dohle, W., et al. Synthesis, antitubulin, and antiproliferative SAR of analogues of 2-methoxyestradiol-3,17-O,O-bis-sulfamate. J. Med. Chem. 53(7), 2942-2951 (2010).|4. Newman, S.P., Foster, P.A., Ho, Y.T., et al. The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers. Br. J. Cancer 97(12), 1673-1682 (2007).|5. Day, J.M., Newman, S.P., Comninos, A., et al. The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells. J. Steroid Biochem. Mol. Biol. 84(2-3), 317-325 (2003).|6. Foster, P.A., Ho, Y.T., Newman, S.P., et al. 2-MeOE2bisMATE and 2-EtE2bisMATE induce cell cycle arrest and apoptosis in breast cancer xenografts as shown by a novel ex vivo technique. Breast Cancer Res. Treat. 111(2), 251-260 (2008).|7. Chander, S.K., Foster, P.A., Leese, M.P., et al. In vivo inhibition of angiogenesis by sulphamoylated derivatives of 2-methoxyoestradiol. Br. J. Cancer 96(9), 1368-1376 (2007). |
m.cnreagent.com